vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and NORTH EUROPEAN OIL ROYALTY TRUST (NRT). Click either name above to swap in a different company.

NORTH EUROPEAN OIL ROYALTY TRUST is the larger business by last-quarter revenue ($2.2M vs $1.8M, roughly 1.3× INVO Fertility, Inc.). NORTH EUROPEAN OIL ROYALTY TRUST runs the higher net margin — 87.2% vs -150.5%, a 237.7% gap on every dollar of revenue. On growth, NORTH EUROPEAN OIL ROYALTY TRUST posted the faster year-over-year revenue change (329.5% vs 22.6%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

North European Oil Royalty Trust is a publicly traded royalty trust holding overriding royalty interests in North Sea oil and gas producing properties. It earns revenue from its assets' production sales, distributing nearly all net income to unitholders regularly, with no active drilling or exploration operations.

IVF vs NRT — Head-to-Head

Bigger by revenue
NRT
NRT
1.3× larger
NRT
$2.2M
$1.8M
IVF
Growing faster (revenue YoY)
NRT
NRT
+306.9% gap
NRT
329.5%
22.6%
IVF
Higher net margin
NRT
NRT
237.7% more per $
NRT
87.2%
-150.5%
IVF

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
IVF
IVF
NRT
NRT
Revenue
$1.8M
$2.2M
Net Profit
$-2.6M
$1.9M
Gross Margin
Operating Margin
-93.1%
Net Margin
-150.5%
87.2%
Revenue YoY
22.6%
329.5%
Net Profit YoY
-62.2%
581.3%
EPS (diluted)
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
NRT
NRT
Q1 26
$2.2M
Q3 25
$1.8M
Q2 25
$1.9M
Q1 25
$1.6M
$519.4K
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$1.8M
Q1 24
$1.6M
Net Profit
IVF
IVF
NRT
NRT
Q1 26
$1.9M
Q3 25
$-2.6M
Q2 25
$-5.3M
Q1 25
$-17.4M
$285.5K
Q4 24
$-3.6M
Q3 24
$-1.6M
Q2 24
$-2.2M
Q1 24
$-1.6M
Gross Margin
IVF
IVF
NRT
NRT
Q1 26
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Operating Margin
IVF
IVF
NRT
NRT
Q1 26
Q3 25
-93.1%
Q2 25
-160.4%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-100.9%
Q1 24
-95.7%
Net Margin
IVF
IVF
NRT
NRT
Q1 26
87.2%
Q3 25
-150.5%
Q2 25
-283.6%
Q1 25
-1060.1%
55.0%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-122.2%
Q1 24
-101.3%
EPS (diluted)
IVF
IVF
NRT
NRT
Q1 26
Q3 25
$-0.77
Q2 25
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-15.11
Q2 24
$-22.39
Q1 24
$-7.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
NRT
NRT
Cash + ST InvestmentsLiquidity on hand
$3.9M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
Total Assets
$18.8M
$3.9M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
NRT
NRT
Q1 26
$3.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Total Debt
IVF
IVF
NRT
NRT
Q1 26
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
NRT
NRT
Q1 26
Q3 25
$5.8M
Q2 25
$2.6M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$-23.3K
Q2 24
$1.4M
Q1 24
$10.2K
Total Assets
IVF
IVF
NRT
NRT
Q1 26
$3.9M
Q3 25
$18.8M
Q2 25
$19.3M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$17.0M
Q2 24
$17.8M
Q1 24
$17.3M
Debt / Equity
IVF
IVF
NRT
NRT
Q1 26
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
NRT
NRT
Operating Cash FlowLast quarter
$-1.8M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
NRT
NRT
Q1 26
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-1.5M
Q1 24
$-260.6K
Free Cash Flow
IVF
IVF
NRT
NRT
Q1 26
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
FCF Margin
IVF
IVF
NRT
NRT
Q1 26
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Capex Intensity
IVF
IVF
NRT
NRT
Q1 26
Q3 25
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons